NCT06814938Active, not recruitingPhase 4
A Study of a Novel Precision Medicine Approach For Obesity
A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- First submitted
- 3 Feb 2025
- Start date
- 21 Feb 2025
- Primary completion date
- Dec 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Obesity
- NCT number
- NCT06814938
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 135
- From 21 Feb 2025 to the primary completion date, Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight changes greater than 3% in the previous 3 months
Other illness
- History of bariatric surgery including lap band and bariatric endoscopy
- Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score \>11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
- Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
Other
- Any contraindication to FDA-approved GLP1R agonists
- A person who is pregnant or wanting to become pregnant
- Once the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
- A family member who is enrolled in this study.
- Principal Investigator Discretion
Who the study is looking for
- \- Obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g., controlled hypertension).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.